Zentalis Pharmaceuticals Llc Stock Probability of Future Stock Price Finishing Over 3.34

ZNTL Stock  USD 3.61  0.02  0.55%   
Zentalis Pharmaceuticals' future price is the expected price of Zentalis Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Zentalis Pharmaceuticals Llc performance during a given time horizon utilizing its historical volatility. Check out Zentalis Pharmaceuticals Backtesting, Zentalis Pharmaceuticals Valuation, Zentalis Pharmaceuticals Correlation, Zentalis Pharmaceuticals Hype Analysis, Zentalis Pharmaceuticals Volatility, Zentalis Pharmaceuticals History as well as Zentalis Pharmaceuticals Performance.
  
The value of Price To Sales Ratio is estimated to slide to about 23.9 K. The value of Price Earnings Ratio is estimated to slide to -3.56. Please specify Zentalis Pharmaceuticals' target price for which you would like Zentalis Pharmaceuticals odds to be computed.

Zentalis Pharmaceuticals Target Price Odds to finish over 3.34

The tendency of Zentalis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 3.34  in 90 days
 3.61 90 days 3.34 
about 54.85
Based on a normal probability distribution, the odds of Zentalis Pharmaceuticals to stay above $ 3.34  in 90 days from now is about 54.85 (This Zentalis Pharmaceuticals Llc probability density function shows the probability of Zentalis Stock to fall within a particular range of prices over 90 days) . Probability of Zentalis Pharmaceuticals price to stay between $ 3.34  and its current price of $3.61 at the end of the 90-day period is about 25.27 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.7 . This usually means as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Zentalis Pharmaceuticals will likely underperform. Additionally Zentalis Pharmaceuticals Llc has an alpha of 0.0619, implying that it can generate a 0.0619 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Zentalis Pharmaceuticals Price Density   
       Price  

Predictive Modules for Zentalis Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zentalis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Zentalis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.183.639.42
Details
Intrinsic
Valuation
LowRealHigh
3.2514.9620.75
Details
Naive
Forecast
LowNextHigh
0.073.539.32
Details
11 Analysts
Consensus
LowTargetHigh
45.1449.6055.06
Details

Zentalis Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Zentalis Pharmaceuticals is not an exception. The market had few large corrections towards the Zentalis Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Zentalis Pharmaceuticals Llc, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Zentalis Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.06
β
Beta against Dow Jones2.70
σ
Overall volatility
0.41
Ir
Information ratio 0.05

Zentalis Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zentalis Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zentalis Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Zentalis Pharmaceuticals had very high historical volatility over the last 90 days
Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 0.
Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company outstanding shares are owned by institutional investors
Latest headline from gurufocus.com: Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Zentalis Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Zentalis Stock often depends not only on the future outlook of the current and potential Zentalis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zentalis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding65.4 M
Cash And Short Term Investments482.9 M

Zentalis Pharmaceuticals Technical Analysis

Zentalis Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Zentalis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Zentalis Pharmaceuticals Llc. In general, you should focus on analyzing Zentalis Stock price patterns and their correlations with different microeconomic environments and drivers.

Zentalis Pharmaceuticals Predictive Forecast Models

Zentalis Pharmaceuticals' time-series forecasting models is one of many Zentalis Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Zentalis Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Zentalis Pharmaceuticals

Checking the ongoing alerts about Zentalis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Zentalis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Zentalis Pharmaceuticals had very high historical volatility over the last 90 days
Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 0.
Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company outstanding shares are owned by institutional investors
Latest headline from gurufocus.com: Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.50)
Revenue Per Share
0.572
Return On Assets
(0.25)
Return On Equity
(0.43)
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.